No profile data available.
Surrozen, Inc. (SRZN) is a healthcare company in the eye treatment pharmaceuticals industry, based in South San Francisco, United States, with about 44 full-time employees.
It reported revenue of $10.66 million for fiscal year 2024, and net income of -$63.56 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $983,000, down 90.2% from a year before. Its market capitalization was $348.96 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Surrozen reported $10.66 million in revenue for fiscal year 2024. In Q3 2025 revenue was $983,000.
$348.96 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Kodiak Sciences Inc. (KOD), MeiraGTx Holdings plc (MGTX), Opus Genetics, Inc. (IRD), Ocugen, Inc. (OCGN).